The press regularly reports on the results of IQWiG's work or asks the Institute’s researchers to comment on current developments and issues. A selection of recent articles is presented below:
In an interview with Deutsches Ärzteblatt, IQWiG-Director Thomas Kaiser explains how evidence can be better communicated in medicine and why other European countries do it better.
In an interview with the newspaper “Kölner Stadtanzeiger”, IQWiG's Director, Thomas Kaiser, explains the tasks of the Cologne-based Institute and why it is of national importance.
The necessary data for a reliable benefit assessment of many procedures is still lacking. Stefan Sauerland explains in the Tagesspiegel Background what this means for the treatment of patients.
Stefan Sauerland, Head of IQWiG's Department of Non-Drug Interventions, answers these and other questions about the advantages and disadvantages of health checks on Deutschlandfunk radio.
Klaus Koch, Head of the Department of Health Information at IQWiG, explains in an interview with “Planet Wissen” why not every screening test is beneficial and can also be detrimental.
Thomas Kaiser, Director of the Institute, wonders in “Observer Gesundheit” about the staged uproar of the German Federal Association of the Pharmaceutical Industry over requirements allegedly demanded for the approval of drugs.
Stefan Sauerland, Head of IQWiG's Department of Non-Drug Interventions, explains to MDR when and up to when breast cancer screening can be beneficial and what is important.
In his first interview as IQWiG's new Director, Thomas Kaiser talks to Ärzte Zeitung about expensive drugs, sloppy researchers - and about the potentially largest registry study in the world.
In his last interview as the Director of IQWiG, Jürgen Windeler takes stock of his 12 years in office in an interview with the weekly newspaper Die ZEIT.
Many medical studies are published late or not at all. On SWR2, Stefan Sauerland, Head of IQWiG's Non-Drug Interventions Department, explains why this is problematic.
After several scandals involving medical devices, a new EU regulation came into force in 2021. In the magazine "Gute Pillen - schlechte Pillen" (Good Pills - Bad Pills), Stefan Sauerland, Head of IQWiG's Department of Non-Drug Interventions, explains the benefits of the regulation for patients.
